Peter Gagianas, MD
Family Medicine · Mc Murray, PANPI 1417975384
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $8,473 of the $10,082 with a category attached, or 84.0%. Novo Nordisk AS accounts for 85.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $9,087 and has fallen 99.8% since, to $20 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $113.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$9K
- Novo Nordisk$308
- GSK$242
- AbbVie$177
- Amgen$151
- Lilly USA, LLC$78
- plus $508 from 15 others
Across 327 payments — averaging $571.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$100K
- Esperion Therapeutics, Inc.$87K
What the payments were for
- Travel & lodging$8,47384%
- Food & beverage$1,46014%
- Education$1481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 7 | $8,617 |
| Novo Nordisk | 12 | $308 |
| GSK | 16 | $242 |
| AbbVie | 8 | $177 |
| Amgen | 10 | $151 |
| Lilly USA, LLC | 6 | $78 |
| Pfizer | 4 | $67 |
| Biohaven Pharmaceuticals, Inc. | 4 | $60 |
| Astellas Pharma US Inc | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $41 |
| Pulmonx Corporation | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Novartis | 1 | $21 |
| Si-bone, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Merck | 1 | $14 |
| Bayer | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$8,487
How this compares
$10,082 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $90,285 |
| JardianceEmpagliflozin | 102 | $89,684 |
| EliquisApixaban | 125 | $88,969 |
| TrulicityDulaglutide | 40 | $55,845 |
| MounjaroTirzepatide | 41 | $44,400 |
| XareltoRivaroxaban | 41 | $38,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,513 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $18,497 |
| TradjentaLinagliptin | 28 | $17,314 |
| MyrbetriqMirabegron | 15 | $10,493 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $8,773 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $7,490 |
| FarxigaDapagliflozin Propanediol | 12 | $7,241 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,342 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 90 | $5,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $41 | $113,340142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $78 | $100,24481 claims |
| Novo NordiskOzempic | $308 | $90,28577 claims |
| PfizerEliquis | $67 | $88,969125 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $242 | $26,00343 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $10,49315 claims |
| AbbVieSynthroid | $177 | $4,85681 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Mc Murray
- John BarrettMc Murray$30K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.